1. Volume 388, Issue 10056, Pages 2153-2163 (October 2016)
Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo- controlled study 
Dr Prof Jacqueline A French, MD, John A Lawson, MD, Prof Zuhal Yapici, MD, Hiroko Ikeda, MD, Tilman Polster, MD, Rima Nabbout, MD, Prof Paolo Curatolo, MD, Prof Petrus J de Vries, PhD, Dennis J Dlugos, MD, Noah Berkowitz, MD, Maurizio Voi, MD, Severine Peyrard, MS, Diana Pelov, MS, Prof David N Franz, MD 
The Lancet 
Volume 388, Issue 10056, Pages (October 2016)
DOI: /S (16)
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
AEDs=antiepileptic drugs. *A patient could have had multiple reasons for screen failure. †Everolimus trough concentrations.
The Lancet  , DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

3. Figure 2 Seizure outcomes
(A) Response rate by treatment group. Bars represent 95% CIs. (B) Median percentage reduction in seizure frequency by treatment group. Bars represent 95% CIs. (C) Distribution of reduction from baseline in seizure frequency by treatment group. (D) Response rate among various seizure types. Numbers on the x axis denoxste the number of patients with at least one occurrence of the seizure type during the baseline phase; bars represent 95% CIs. (E) Median percentage change from baseline in seizure frequency. (F) Median percentage of seizure-free days.
The Lancet  , DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions